Resistentia Pharmaceuticals AB, a privately held biotechnology company developing
innovative immunotherapies, has announced the closing of a EUR 11 million financing. The funds will be used to advance the clinical development of RP01, Resistentia’s novel universal allergy immunotherapy, into phase II clinical trials.
The financing was led by SR One, GlaxoSmithKline’s independent corporate healthcare venture capital fund, a new investor in Resistentia. The company’s major investors, HealthCap, Industrifonden, BankInvest and Innovationskapital, as well as several other investors, also participated in the financing.
“We are delighted to welcome SR One as an investor in Resistentia. Their entry into an already strong investor syndicate further validates Resistentia’s international attraction and reinforces confidence in our novel immunotherapies,” said Marcus Bosson, CEO Resistentia Pharmaceuticals. “The new money, I am pleased to say, will allow us to accelerate our clinical development program.”
Kent Gossett, Principal at SR One, was elected to Resistentia Pharmaceuticals’ Board of Directors at an EGM on August 14. "SR One is enthusiastic to join such a quality investor syndicate and management team in developing Resistentia's breakthrough therapies for patients with asthma, allergies and other inflammatory conditions," he said.
For further information, please contact:
Marcus Bosson, Chief Executive Officer
+46 18 65 39 01, +46 70 693 82 81 or email@example.com
About Resistentia Pharmaceuticals
Resistentia Pharmaceuticals AB is a Swedish privately held biotech company developing innovative immunotherapies that target allergy and asthma as well as inflammatory disorders. Founded in 1998, the company has developed an industrial organization with experiences ranging from molecular immunology, pre-clinical and clinical drug development to industrial biopharmaceutical production. In addition to its lead anti-IgE immunotherapeutic, Resistentia has initiated pre-clinical development of an immunotherapeutic against complement factor C5a for the treatment of rheumatoid arthritis and other autoimmune diseases.
RP01 is an immunotherapeutic that stimulates the immune system to produce antibodies against IgE (Immunoglobulin E), the key mediator of allergic reactions. The antibodies bind to IgE, thereby blocking it from causing allergic reactions. Such a mechanism of action is efficient regardless of what triggers the allergy, be it pollen, grass, dust mites, foodstuffs or pets.
Data from a phase I clinical trial show that RP01 is safe and well tolerated and that the participants developed anti-IgE antibodies, supporting the immunotherapy’s novel mode of action. RP01 will primarily target allergic asthma. Other potential indications include allergic rhinitis and peanut allergy.
About SR One
SR One is GlaxoSmithKline’s independent corporate healthcare venture capital fund based in West Conshohocken, Pennsylvania (USA), and London, UK. SR One invests globally in emerging drug discovery, development and delivery companies with novel products that have the potential to provide dramatic patient benefit. Since its founding in 1985, SR One has invested over USD 400 million in more than 120 emerging biotechnology companies.
>>> Discuss This Story